Article Abstract

Broader indications for checkpoint inhibitors in NSCLC

Authors: Anders Mellemgaard

Abstract

It has been 23 years since the results from a meta-analysis of several randomized trials comparing first line chemotherapy with best supportive care for metastatic non-small cell lung cancer (NSCLC) was published (1).